首页> 美国卫生研究院文献>Medicina >Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis
【2h】

Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis

机译:手术边缘宽度是否仍然是三阴性乳腺癌的挑战?回顾性分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and Objectives: Local and distant relapse (LR, DR) in breast cancer vary according to its molecular subtypes, with triple-negative breast cancer (TNBC) being the most aggressive. The surgical resection margin width (SRMW) for breast-conserving surgery (BCS) has been intensely debated, especially for the aforementioned subtype. The aim of this study was to examine the impact of SRMW on LR following BCS in TNBC patients. Materials and Methods: We conducted a retrospective study including all patients with TNBC for whom BCS was performed between 2005 and 2014. Results: Final analysis included a total of 92 patients, with a median tumor size of 2.5 cm (range 0–5 cm) and no distant metastasis at the time of diagnosis. A total of 87 patients had received neoadjuvant and/or adjuvant chemotherapy, and all patients had received adjuvant whole-breast radiotherapy. After a median follow-up of 110.7 months (95% CI, 95.23–126.166), there were 5 local recurrences and 8 regional/distant recurrences with an overall LR rate of 5.4%. The risk of LR and DR was similar between groups of patients with several SRMW cut-off values. Conclusions: Our study supports a safe “no ink on tumor” approach for TNBC patients treated with BCS.
机译:背景和目标:乳腺癌局部和遥远的复发(LR,DR)根据其分子亚型而变化,具有三重阴性乳腺癌(TNBC)是最具侵略性的。用于哺乳的手术(BCS)的外科切除缘宽度(SRMW)一直密切争论,特别是对于上述亚型。本研究的目的是检验SRMW对TNBC患者的BCS后的SRMW对LR的影响。材料和方法:我们进行了一种回顾性研究,包括所有患有BCS的TNBC患者,其中BC在2005年至2014年之间进行。结果:终点分析包括共92名患者,中位肿瘤大小为2.5厘米(范围0-5厘米)在诊断时没有遥远的转移。共有87名患者接受了Neoadjuvant和/或辅助化疗,所有患者均接受了佐剂全乳房放射治疗。在110.7个月的中位随访后(95%CI,95.23-126.166),有5个局部复发和8个区域/遥远的复发,整体LR率为5.4%。 LR和DR的风险在具有几个SRMW截止值的患者组之间类似。结论:我们的研究支持用BCS治疗的TNBC患者安全的“肿瘤上的肿瘤”方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号